This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seo, J.-Y. Articles by Jeong, S. Y. Search for Related Content PubMed PubMed Citation Articles by Seo, J.-Y. Articles by Jeong, S. Y.

 Previous Article  |  Next Article 

Infection and Immunity, March 2002, p. 1143-1149, Vol. 70, No. 3
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.3.1143-1149.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Cross-Protective Immunity of Mice Induced by Oral Immunization with Pneumococcal Surface Adhesin A Encapsulated in Microspheres

Jun-Young Seo,^1,2, Seung Yong Seong,³ Byung-Yoon Ahn,² Ick Chan Kwon,¹ Hesson Chung,¹ and Seo Young Jeong^1*

Biomedical Research Center, Korea Institute of Science and Technology, Seoul 136-791,,¹ Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 110-799 ,³ Graduate School of Biotechnology, Korea University, Seoul 136-701, Korea²

Received 10 September 2001/ Returned for modification 24 October 2001/ Accepted 4 December 2001

The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.

Present address: Cellular and Molecular Biology Graduate Program, University of Alabama at Birmingham, Birmingham, AL 35294.

This article has been cited by other articles:

• Villena, J., Racedo, S., Aguero, G., Bru, E., Medina, M., Alvarez, S. (2005). Lactobacillus casei Improves Resistance to Pneumococcal Respiratory Infection in Malnourished Mice. J. Nutr. 135: 1462-1469 [Abstract] [Full Text]  
• Romero-Steiner, S., Pilishvili, T., Sampson, J. S., Johnson, S. E., Stinson, A., Carlone, G. M., Ades, E. W. (2003). Inhibition of Pneumococcal Adherence to Human Nasopharyngeal Epithelial Cells by Anti-PsaA Antibodies. CVI 10: 246-251 [Abstract] [Full Text]